A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Elexacaftor/vacaftor/tezacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 24 May 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2018 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 New Source identified and integrated: European Clinical Trials Database (EudraCT2018-000185-11)